Sign inJoin waitlistJoin the waitlist

Steven Attia

Oncologist · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Medical Oncology
2004–2006
Internal Medicine
2001–2004
Doctor of Osteopathic Medicine
1997–2001

Research

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
The Lancet Oncology · 2017 · 1,203 citations
Sorafenib for Advanced and Refractory Desmoid Tumors
New England Journal of Medicine · 2018 · 355 citations
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
The Lancet Oncology · 2020 · 352 citations

BT
Brian Van Tine
23 papers
SC
Sant Chawla
16 papers
Scott Okuno
16 papers
Richard Riedel
15 papers
Mark Agulnik
14 papers
Margaret von Mehren
11 papers
Suzanne George
11 papers
RM
Robert Maki
10 papers
Kristen Ganjoo
9 papers
Lara Davis
9 papers
MB
Melissa Burgess
9 papers
RJ
Robin Jones
9 papers

Clinical trials

Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2009–2011
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
Site PI · Recruiting · Phase 2
Eli Lilly and Company
2020–2027
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
Site PI · Unknown · Phase 1
CBA Research
2018–2020